About | Free Trial

Last Update

2016-04-12T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Anthony Rosenberg?

Mr. Anthony Rosenberg

Head of Global Business Development and Licensing

Novartis AG

Direct Phone: +41 ***********       

Email: a***@***.com

Novartis Pharma AG

Novartis AG

One Health Plaza

East Hanover, New Jersey 07936

United States

Company Description

Novartis AG is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare products. The Company�s healthcare solutions portfolio includes medicines, preventive vaccines and ... more

Find other employees at this company (47,824)

Background Information

Affiliations

Head Partnering and Emerging Businesses, Member
Executive Committee Novartis Pharma AG

Member
PECS

Education

Bachelor of Science degree
Biological Sciences
University of Leicester

Masters of Science
Physiology
University of London

Web References (154 Total References)


The current Class I Directors are ...

www.sec.gov, $reference.date [cached]

The current Class I Directors are Owen Hughes, Debasish Roychowdhury, M.D. and Robert E. Ward; the current Class II Directors are Alan H. Auerbach, Catherine J. Friedman, Ansbert K. Gadicke, M.D., and Jean-Pierre Garnier; and the current Class III Directors are Willard H. Dere, M.D., Kurt C. Graves and Anthony Rosenberg.

...
Anthony Rosenberg
...
ANTHONY ROSENBERG
...
Anthony Rosenberg has served on our Board of Directors since March 2015. Mr. Rosenberg has been a Managing Director of MPM Capital, a venture capital firm, since April 2015. From January 2013 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis International, a pharmaceutical company. From March 2005 to December 2012, he served as Global Head of Business Development and Licensing at Novartis Pharmaceuticals. Prior to that, Mr. Rosenberg was Global Head of the Transplant and Immunology Business Unit at Novartis Pharmaceuticals from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. He currently serves as a director of Clinical Ink and TriNetX. Mr. Rosenberg served as a director of Idenix Pharmaceuticals, Inc. from June 2009 to March 2012 and from December 2012 to March 2013. Mr. Rosenberg holds a B.Sc from the University of Leicester and an M.Sc in physiology from the University of London. We believe Mr. Rosenberg is qualified to serve as a member of our Board of Directors due to his extensive experience in mergers and acquisitions and licensing in the pharmaceutical sector.
...
Our Board of Directors currently consists of ten (10) members: Alan H. Auerbach, Willard H. Dere, M.D., Catherine J. Friedman, Ansbert K. Gadicke, M.D., Jean-Pierre Garnier, Kurt C. Graves, Owen Hughes, Anthony Rosenberg, Debasish Roychowdhury, M.D., and Robert E. Ward.
...
Our Board of Directors has affirmatively determined that each of Alan H. Auerbach, Willard H. Dere, M.D., Catherine J. Friedman, Ansbert K. Gadicke, M.D., Jean-Pierre Garnier, Kurt C. Graves, Owen Hughes, Anthony Rosenberg, and Debasish Roychowdhury, M.D., is an "independent director," as defined under NASDAQ rules.
...
Anthony Rosenberg, a Class III director elected to the Board in 2015, was recommended by a non-management director.


BIOCOM's 2nd Annual Global Life Science Partnering Conference | Life Science Branding & Marketing Network

www.lsbmn.org, $reference.date [cached]

Tony Rosenberg, Head of Global BD & Licensing, Novartis


Tony ...

www.radiuspharm.com, $reference.date [cached]

Tony Rosenberg

...
Tony Rosenberg is retired from Novartis where he was Head of M&A and Licensing. Most recently he was responsible for the Portfolio Transformation transactions undertaken by Novartis, which are seen as landmark deals in the industry.
Tony joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basle, initially in international product management (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit. In 2005 he was appointed Global Head Business Development & Licensing (Pharma) and has managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestment and M&A deals. In 2010 he was given additional responsibility for leadership of the Molecular Diagnostics group. In 2013 he was appointed as Head M&A and Licensing (Corporate).
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.


The current Class I Directors are ...

ir.radiuspharm.com, $reference.date [cached]

The current Class I Directors are Owen Hughes, Elizabeth Stoner, M.D. and Robert E. Ward; the current Class II Directors are Alan H. Auerbach, Ansbert K. Gadicke, M.D. and Martin Münchbach, Ph.D; and the current Class III Directors are Willard H. Dere, M.D., Kurt C. Graves and Anthony Rosenberg.

...
Anthony Rosenberg
...
ANTHONY ROSENBERG
...
Anthony Rosenberg has served on our Board of Directors since March 2015. From January 2013 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis International, a pharmaceutical company. From March 2005 to December 2012, he served as Global Head of Business Development and Licensing at Novartis Pharmaceuticals. Prior to that, Mr. Rosenberg was Global Head of the Transplant and Immunology Business Unit at Novartis Pharmaceuticals from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. Mr. Rosenberg served as a director of Idenix Pharmaceuticals, Inc. from June 2009 to March 2012 and from
...
Mr. Rosenberg holds a B.Sc from the University of Leicester and an M.Sc in physiology from the University of London. We believe Mr. Rosenberg is qualified to serve as a member of our Board of Directors due to his extensive experience in mergers and acquisitions and licensing in the pharmaceutical sector.
...
Our Board of Directors currently consists of nine (9) members: Alan H. Auerbach, Willard H. Dere, M.D., Ansbert K. Gadicke, M.D., Kurt C. Graves, Owen Hughes, Martin Münchbach, Ph.D., Anthony Rosenberg, Elizabeth Stoner, M.D. and Robert E. Ward.
...
Our Board of Directors has affirmatively determined that each of Alan H. Auerbach, Willard H. Dere, M.D., Ansbert K. Gadicke, M.D., Kurt C. Graves, Owen Hughes, Martin Münchbach, Ph.D., Anthony Rosenberg and Elizabeth Stoner, M.D. is an "independent director," as defined under NASDAQ rules.
...
Anthony Rosenberg


Anthony ...

www.bioexecinstitute.org, $reference.date [cached]

Anthony Rosenberg

...
Anthony Rosenberg
Managing Director, MPM Capital

Similar Profiles

Other People with this Name (18,032)

Other people with the name Rosenberg

William Rosenberg
The Mask and Wig Club

Ronni Rosenberg
Sheridan College

Paul Rosenberg
Calgary Stampede

Robert Rosenberg
Arthritis and Rheumatism Associates P.C

Dave Rosenberg
US Austrians

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory